A5076234152- Hematopoietic Stem Cell Transplantation
- Cytomegalovirus and herpesvirus research
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Immunodeficiency and Autoimmune Disorders
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Parvovirus B19 Infection Studies
- Neuroblastoma Research and Treatments
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Platelet Disorders and Treatments
- Renal Transplantation Outcomes and Treatments
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Herpesvirus Infections and Treatments
- Blood groups and transfusion
Texas Children's Hospital
2016-2025
Baylor College of Medicine
2016-2025
Children's Cancer Center
2010-2025
Houston Methodist
2015-2024
Methodist Hospital
2015-2024
Dan L Duncan Comprehensive Cancer Center
2013-2024
Cell Medica (Switzerland)
2017
Bristol-Myers Squibb (Switzerland)
2017
Cell Medica (United Kingdom)
2017
GlaxoSmithKline (India)
2017
Cellular therapies could play a role in cancer treatment and regenerative medicine if it were possible to quickly eliminate the infused cells case of adverse events. We devised an inducible T-cell safety switch that is based on fusion human caspase 9 modified FK-binding protein, allowing conditional dimerization. When exposed synthetic dimerizing drug, (iCasp9) becomes activated leads rapid death expressing this construct.We tested activity our by introducing gene into donor T given enhance...
Purpose Improvement of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from severe viral infections. Adoptively transferred virus-specific T cells (VSTs) generated eligible, third-party donors could provide broad antiviral protection recipients HSCT as an immediately available off-the-shelf product. Patient and Methods We a bank VSTs that recognized five common pathogens: Epstein-Barr...
Rapidly generated broad-spectrum T cells can simultaneously treat multiple viral infections after hematopoietic stem cell transplant.
Adoptive transfer of virus-specific T cells can prevent and treat serious infections with Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (Adv) after allogeneic hematopoietic stem cell transplant. It has, however, proved difficult to make this approach widely available since infectious viral vectors are required for activation, followed by an intensive prolonged culture period extending over several months. We now show that targeting a range antigens derived from EBV, CMV, Adv be...
Abstract Purpose: GVHD after allogeneic hematopoietic stem cell transplantation (alloSCT) has been associated with low numbers of circulating CD4+CD25+FoxP3+ regulatory T cells (Tregs). Because Tregs express high levels the interleukin (IL)-2 receptor, they may selectively expand in vivo response to doses IL-2 insufficient stimulate effector T-cell populations, thereby preventing GVHD. Experimental Design: We prospectively evaluated effects ultra low-dose (ULD) injections on Treg recovery...
Abstract Purpose: Viral infections are a major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). In the absence safe effective antiviral treatments, virus-specific T cells have emerged as promising therapeutic option. Posoleucel is multivirus-specific T-cell therapy for off-the-shelf use against six viral that commonly occur in allo-HCT recipients: adenovirus, BK virus (BKV), cytomegalovirus, Epstein–Barr virus, human herpes virus-6, JC...
Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a common, usually fatal, complication developing after transplantation of bone marrow from HLA-mismatched or HLA-matched unrelated donors. Prompted by recent reports successful treatment EBV-LPD, we investigated methods which could result in early identification patients at high risk for this disorder, thus improving the likelihood therapeutic interventions. Both outgrowth transformed B lymphocytes ex vivo (100%...
Treatment of the central nervous system is crucial to successful treatment acute lymphoblastic leukemia in children. The intensity and timing therapy are based on presence or predicted risk as assessed according criteria that remain controversial.The clinical importance leukemic blast cells detected cerebrospinal fluid at time diagnosis was evaluated 351 children with a randomized trial intensive chemotherapy. All patients received intrathecal chemotherapy during first year. Patients...